Skip to main navigation Skip to main content

Clin Mol Hepatol : Clinical and Molecular Hepatology

OPEN ACCESS
ABOUT
BROWSE ARTICLES
FOR CONTRIBUTORS

Page Path

4
results for

"Hoon Choi"

Article category

Keywords

Publication year

"Hoon Choi"

Original Articles

Liver Transplantation

Impact of everolimus on survival after liver transplantation for hepatocellular carcinoma
Incheon Kang, Jae Geun Lee, Sung Hoon Choi, Hyun Jeong Kim, Dai Hoon Han, Gi Hong Choi, Myoung Soo Kim, Jin Sub Choi, Soon Il Kim, Dong Jin Joo
Clin Mol Hepatol 2021;27(4):589-602.
Published online July 23, 2021
DOI: https://doi.org/10.3350/cmh.2021.0038
Background/Aims
This study aimed to investigate whether everolimus (EVR) affects long-term survival after liver transplantation (LT) in patients with hepatocellular carcinoma (HCC).
Methods
The data from 303 consecutive patients with HCC who had undergone LT from January 2012 to July 2018 were retrospectively reviewed. The patients were divided into two groups: 1) patients treated with EVR in combination with calcineurin inhibitors (CNIs) (EVR group; n=114) and 2) patients treated with CNI-based therapy without EVR (non-EVR group; n=189). Time to recurrence (TTR) and overall survival (OS) after propensity score (PS) matching were compared between the groups, and prognostic factors for TTR and OS were evaluated.
Results
The EVR group exhibited more aggressive tumor biology than the non-EVR group, such as a higher number of tumors (P=0.003), a higher prevalence of microscopic vascular invasion (P=0.017) and exceeding Milan criteria (P=0.029). Compared with the PS-matched non-EVR group, the PS-matched EVR group had significantly better TTR (P<0.001) and OS (P<0.001). In multivariable analysis, EVR was identified as an independent prognostic factor for TTR (hazard ratio [HR], 0.248; P=0.001) and OS (HR, 0.145; P<0.001).
Conclusions
Combined with CNIs, EVR has the potential to prolong long-term survival in patients undergoing LT for HCC. These findings warrant further investigation in a well-designed prospective study.

Citations

Citations to this article as recorded by  Crossref logo
  • Dual role of icaritin in attenuating allograft rejection and exerting antitumor effects in mice
    Jinliang Duan, Shaofeng Chen, Yang Wang, Dejun Kong, Zhenglu Wang, Lei Cao, Wei Rao, Tao Chen, Sei Yoshida, Zhenzhou Wu, Hong Zheng, Zhongyang Shen
    Frontiers in Immunology.2026;[Epub]     CrossRef
  • Clinical Impact and Cost-effectiveness of Everolimus Combination Therapy in Liver Transplant Recipients: Focus on the Risk of Cancer, Infection, and Renal Function
    Suk-Chan Jang, Gi-Ae Kim, Young-Suk Lim, Hye-Lin Kim, Eui-Kyung Lee
    Transplantation.2026; 110(7): e1437.     CrossRef
  • Conference recommendations on immunosuppression practice for adult liver transplantation in Egypt
    Nahed A Makhlouf, Iman F Montasser, Rasha Refaie, Yasmine M Massoud, Ahmed Marwan, Ehab Abdel-Khalek, Hadeel Gamal Eldeen, Mohamad EL Tabbakh, Mohamed Said, Wahid Doss, Ayman Yosry, Mohamed Sherif Mogawer, Mohamed El-Saadany, Mohammad Amin Sakr, Imam Wake
    Egyptian Liver Journal.2026;[Epub]     CrossRef
  • Everolimus Personalized Therapy: Second Consensus Report by the International Association of Therapeutic Drug Monitoring and Clinical Toxicology
    Satohiro Masuda, Florian Lemaitre, Markus J. Barten, Stein Bergan, Maria Shipkova, Teun van Gelder, Sander Vinks, Eberhard Wieland, Kirsten Bornemann-Kolatzki, Mercè Brunet, Brenda de Winter, Maja-Theresa Dieterlen, Laure Elens, Taihei Ito, Kamisha Johnso
    Therapeutic Drug Monitoring.2025; 47(1): 4.     CrossRef
  • Genetic alterations are related to clinicopathological features and risk of recurrence/metastasis of hepatocellular carcinoma
    Lili Meng, Zhenjian Jiang, Guangyue Shen, Shulan Lin, Feng Gao, Xinxin Guo, Bin Lv, Shuying Hu, Zheng Ni, Shanghua Chen, Yuan Ji
    European Journal of Cancer Prevention.2025; 34(5): 456.     CrossRef
  • Association between everolimus combination therapy and cancer risk after liver transplantation: A nationwide population-based quasi-cohort study
    Suk-Chan Jang, Gi-Ae Kim, Young-Suk Lim, Hye-Lin Kim, Eui-Kyung Lee
    American Journal of Transplantation.2025; 25(6): 1285.     CrossRef
  • Adjuvant chemotherapy improves post-transplant outcome in patients with hepatocellular carcinoma
    Heng-Kai Zhu, Hai-Bo Mou, Zhuo-Yi Wang, Wu Zhang, Dan Zhu, Si-Yi Zhong, Shu-Sen Zheng, Li Zhuang
    Hepatobiliary & Pancreatic Diseases International.2025; 24(5): 491.     CrossRef
  • Optimizing patient selection and immunosuppression in improving long-term survival after living donor liver transplantation for hepatocellular carcinoma
    JaRyung Han, Young Seok Han
    Annals of Liver Transplantation.2025; 5(1): 1.     CrossRef
  • Cellular Cancer Immunotherapy in the Liver Transplant Population for HCC: An Attractive Therapeutic Option for the Next Decade
    Dongdong Yu, Shuchan Li, Hao Chen, Lidong Wang
    Clinical Transplantation.2025;[Epub]     CrossRef
  • Toward optimized immunosuppression balance in liver transplantation: Clinical insights from lower tacrolimus exposure
    Sung-Min Kim
    Annals of Liver Transplantation.2025; 5(2): 65.     CrossRef
  • High Number of Plasma Exchanges Increases the Risk of Bacterial Infection in ABO-incompatible Living Donor Liver Transplantation
    Mun Chae Choi, Eun-Ki Min, Seung Hyuk Yim, Deok-Gie Kim, Jae Geun Lee, Dong Jin Joo, Myoung Soo Kim
    Transplantation.2024; 108(8): 1760.     CrossRef
  • Asian Pacific Association for the Study of the Liver clinical practice guidelines on liver transplantation
    Dong-Sik Kim, Young-In Yoon, Beom Kyung Kim, Ashok Choudhury, Anand Kulkarni, Jun Yong Park, Jongman Kim, Dong Hyun Sinn, Dong Jin Joo, YoungRok Choi, Jeong-Hoon Lee, Ho Joong Choi, Ki Tae Yoon, Sun Young Yim, Cheon-Soo Park, Deok-Gie Kim, Hae Won Lee, Wo
    Hepatology International.2024; 18(2): 299.     CrossRef
  • Everolimus Mitigates the Risk of Hepatocellular Carcinoma Recurrence after Liver Transplantation
    Paolo De Simone, Arianna Precisi, Quirino Lai, Juri Ducci, Daniela Campani, Piero Marchetti, Stefano Gitto
    Cancers.2024; 16(7): 1243.     CrossRef
  • Liver Transplantation for Hepatocarcinoma: Results over Two Decades of a Transplantation Programme and Analysis of Factors Associated with Recurrence
    María Martínez Burgos, Rocío González Grande, Susana López Ortega, Inmaculada Santaella Leiva, Jesús de la Cruz Lombardo, Julio Santoyo Santoyo, Miguel Jiménez Pérez
    Biomedicines.2024; 12(6): 1302.     CrossRef
  • Hepatocellular carcinoma recurrence after liver transplantation: risk factors, targeted surveillance and management options
    Filippo Pelizzaro, Alberto Ferrarese, Martina Gambato, Alberto Zanetto, Francesco Paolo Russo, Giacomo Germani, Marco Senzolo, Mario Domenico Rizzato, Caterina Soldà, Alessandro Vitale, Enrico Gringeri, Umberto Cillo, Patrizia Burra
    Hepatoma Research.2024;[Epub]     CrossRef
  • Sirolimus improves the prognosis of liver recipients with hepatocellular carcinoma: A single-center experience
    Peng Liu, Xin Wang, Huan Liu, Shu-Xian Wang, Qing-Guo Xu, Lin Wang, Xiao Xu, Jin-Zhen Cai
    Hepatobiliary & Pancreatic Diseases International.2023; 22(1): 34.     CrossRef
  • Liver transplantation for non-alcoholic fatty liver disease: indications and post-transplant management
    Sara Battistella, Francesca D’Arcangelo, Marco Grasso, Alberto Zanetto, Martina Gambato, Giacomo Germani, Marco Senzolo, Francesco Paolo Russo, Patrizia Burra
    Clinical and Molecular Hepatology.2023; 29(Suppl): S286.     CrossRef
  • 2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma

    Journal of Liver Cancer.2023; 23(1): 1.     CrossRef
  • Immunosuppressive Medication Adherence in Patients With Hepatocellular Cancer Who Have Undergo Liver Transplantation: A Case Control Study
    Sami Akbulut, Murat Tamer, Serdar Saritas, Ozlem Unal, Musap Akyuz, Selver Unsal, Zeynep Kucukakcali, Ertugrul Karabulut, Sertac Usta, Sezai Yilmaz
    Transplantation Proceedings.2023; 55(5): 1231.     CrossRef
  • Risk factors for late-onset Pneumocystis jirovecii pneumonia in liver transplant recipients
    Eun-Ki Min, Juhan Lee, Su Jin Jeong, Deok-Gie Kim, Seung Hyuk Yim, Mun Chae Choi, Dong Jin Joo, Myoung Soo Kim, Jae Geun Lee
    International Journal of Infectious Diseases.2023; 131: 166.     CrossRef
  • Metronomic capecitabine with rapamycin exerts an immunosuppressive effect by inducing ferroptosis of CD4+ T cells after liver transplantation in rat
    Hao Wang, Ruining Yang, Zhenglu Wang, Lei Cao, Dejun Kong, Qian Sun, Sei Yoshida, Jiashu Ren, Tao Chen, Jinliang Duan, Jianing Lu, Zhongyang Shen, Hong Zheng
    International Immunopharmacology.2023; 124: 110810.     CrossRef
  • Association between the early high level of serum tacrolimus and recurrence of hepatocellular carcinoma in ABO-incompatible liver transplantation
    Ji Won Han, Jong Young Choi, Eun Sun Jung, Ji Hoon Kim, Hee Sun Cho, Jae-Sung Yoo, Pil Soo Sung, Jeong Won Jang, Seung Kew Yoon, Ho Joong Choi, Young Kyoung You
    World Journal of Gastrointestinal Surgery.2023; 15(12): 2727.     CrossRef
  • Safety of Tacrolimus Monotherapy within 12 Months after Liver Transplantation in the Era of Reduced Tacrolimus and Mycophenolate Mofetil: National Registry Study
    Deok Gie Kim, Sung Hwa Kim, Shin Hwang, Suk Kyun Hong, Je Ho Ryu, Bong-Wan Kim, Young Kyoung You, Donglak Choi, Dong-Sik Kim, Yang Won Nah, Jai Young Cho, Tae-Seok Kim, Geun Hong, Dong Jin Joo, Myoung Soo Kim, Jong Man Kim, Jae Geun Lee
    Journal of Clinical Medicine.2022; 11(10): 2806.     CrossRef
  • 2022 KLCA-NCC Korea Practice Guidelines for the Management of Hepatocellular Carcinoma

    Korean Journal of Radiology.2022; 23(12): 1126.     CrossRef
  • 2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma

    Clinical and Molecular Hepatology.2022; 28(4): 583.     CrossRef
  • Clinical association between tacrolimus intra-patient variability and liver transplantation outcomes in patients with and without hepatocellular carcinoma
    Hyun Jeong Kim, Juhan Lee, Jae Geun Lee, Dong Jin Joo, Myoung Soo Kim
    Scientific Reports.2022;[Epub]     CrossRef
  • The first successful report of liver transplantation from category III donation after circulatory death in South Korea: a case report
    Incheon Kang, Jae-myeong Lee, Jae Geun Lee
    Korean Journal of Transplantation.2022; 36(4): 294.     CrossRef
  • Can hepatocellular carcinoma recurrence be prevented after liver transplantation?
    Jong Man Kim
    Clinical and Molecular Hepatology.2021; 27(4): 562.     CrossRef
  • Human Cytomegalovirus Is Associated with Lower HCC Recurrence in Liver Transplant Patients
    Po-Jung Hsu, Hao-Chien Hung, Jin-Chiao Lee, Yu-Chao Wang, Chih-Hsien Cheng, Tsung-Han Wu, Ting-Jung Wu, Hong-Shiue Chou, Kun-Ming Chan, Wei-Chen Lee, Chen-Fang Lee
    Current Oncology.2021; 28(6): 4281.     CrossRef
  • Immunological Markers, Prognostic Factors and Challenges Following Curative Treatments for Hepatocellular Carcinoma
    Soon Kyu Lee, Sung Won Lee, Jeong Won Jang, Si Hyun Bae, Jong Young Choi, Seung Kew Yoon
    International Journal of Molecular Sciences.2021; 22(19): 10271.     CrossRef
  • Management of Hepatocellular Carcinoma Recurrence after Liver Transplantation
    Filippo Pelizzaro, Martina Gambato, Enrico Gringeri, Alessandro Vitale, Umberto Cillo, Fabio Farinati, Patrizia Burra, Francesco Paolo Russo
    Cancers.2021; 13(19): 4882.     CrossRef
  • 13,344 View
  • 272 Download
  • 30 Web of Science
  • Crossref

Hepatic neoplasm

Radiation-induced abscopal effect and its enhancement by programmed cell death 1 blockade in the hepatocellular carcinoma: A murine model study
Gyu Sang Yoo, Won-Gyun Ahn, Shin-Yeong Kim, Wonseok Kang, Changhoon Choi, Hee Chul Park
Clin Mol Hepatol 2021;27(1):144-156.
Published online December 7, 2020
DOI: https://doi.org/10.3350/cmh.2020.0095
Background/Aims
The abscopal effect, a rare phenomenon induced by radiation, can be reinforced by immunotherapy. Although radiation therapy and immunotherapy are increasingly being utilized for the treatment of hepatocellular carcinoma (HCC), whether immunotherapy could boost the abscopal effect remains unclear. In this study, we aimed to elucidate the immunological mechanisms underlying the abscopal effect induced by the combination of irradiation and immunotherapy in a murine HCC model.
Methods
A syngeneic HCC mouse model was established by transplanting murine Hepa 1–6 HCC cells into both hind legs of immunocompetent C57BL/6 mice. The tumors on the right hind legs were irradiated, and abscopal effects were observed in the non-irradiated tumors on the left hind leg with or without the coadministration of anti-programmed cell death 1 (PD-1) antibodies. Flow cytometric analyses were performed to analyze the distributions of immune cells infiltrating both irradiated and non-irradiated tumors and the tumor-draining lymph nodes (TDLNs).
Results
Administration of 16 Gy in two fractions more effectively inhibited the growth of both irradiated and nonirradiated tumors with higher tumor infiltration of cytotoxic T cells than 8 Gy did in a single fraction. The higher dose also increased activated dendritic cells in TDLNs, which had higher expression of the programmed cell death ligand 1. Coadministration of anti-PD-1 antibodies significantly enhanced the abscopal effect and increased infiltration of activated cytotoxic T cells in both irradiated and non-irradiated tumors.
Conclusions
Our findings show that adding anti-PD-1 therapy to radiation enhanced the abscopal effect in a syngeneic murine model of HCC.

Citations

Citations to this article as recorded by  Crossref logo
  • Immune Predictors of Radiotherapy Outcomes in Cervical Cancer
    Linghao Wang, Jie Zhu, Zequn Ding, Zhiyuan Xie, Xingchen Liu, Feihong Zhang, Xiaojun Liu, Yan Zhang, Haiyan Chen
    Advanced Science.2026;[Epub]     CrossRef
  • Case Report: Pathologic complete response to PRaG therapy in an elderly patient with refractory metastatic gastric cancer
    Jun Lv, Fayi Yu, Linjiang Pan, Yeying Fang, Zhenghong Zhong, Xue Bai, Jinbiao Gao, Zhuxin Wei
    Frontiers in Oncology.2026;[Epub]     CrossRef
  • Clinical Characteristics of Patients With Advanced Hepatocellular Carcinoma Who Transitioned to Subsequent Therapies Following Systemic Therapy
    Kenji Imai, Koji Takai, Masashi Aiba, Shinji Unome, Takao Miwa, Tatsunori Hanai, Hiroyasu Sakai, Yohei Shirakami, Atsushi Suetsugu, Masahito Shimizu
    Cancer Medicine.2026;[Epub]     CrossRef
  • Nervous and immune system crosstalk shapes cancer progression and treatment response
    Mustafa TArdah, Raghda AliBakr, H. Malathi, Vimal Arora, Priya PriyadarshiniNayak, Dilbar Urazbaeva, Mukhayya Djumaniyazova, Sadullayeva Moxinur, Farid KarkonShayan
    Discover Oncology.2026;[Epub]     CrossRef
  • Breaking Barriers in Hepatocellular Carcinoma: Synergistic Potential of Stereotactic Body Radiotherapy Combined With Immunotherapy
    Deepti Sharma, Babu Lal Meena, Divya Khosla
    Journal of Clinical and Experimental Hepatology.2026; 16(5): 103593.     CrossRef
  • Evaluation of the abscopal-like effect of radioimmunotherapy on sentinel lymph nodes in H22 hepatocellular carcinoma via dynamic lymphography
    Hui Wang, Dengyun Chen, Zhehan Liu, Xuefeng Zhao, Jinzhou Zhang, Dan Zhang
    BMC Cancer.2026;[Epub]     CrossRef
  • Immune microenvironment and immunotherapy in hepatocellular carcinoma: mechanisms and advances
    Dong Xie, Yang Liu, Fangbiao Xu, Zhibo Dang, Mengge Li, Qinsheng Zhang, Zhongqin Dang
    Frontiers in Immunology.2025;[Epub]     CrossRef
  • Radiosensitization strategies for hepatocellular carcinoma: Mechanisms, therapeutic advances, and clinical perspectives
    Jiahui Yang, Rong Chen
    Critical Reviews in Oncology/Hematology.2025; 213: 104773.     CrossRef
  • Stereotactic body radiation therapy (SBRT) increases anti-PD-1 antitumor activity by enhancing the tumor immune microenvironment in mice with metastatic hepatocellular carcinoma
    Ke Xu, Tao Gu, Ke Su, Xin Liu, Bingsheng He, Jie He, Hao Chi, Xuancheng Zhou, Hanlin Liu, Rui Xiao, Xue Tang, Qinni Ye, Xue Zhou, Yingpeng Liu, Jie Xiong, Pan Wang, Han Li, Kun He, Lu Guo, Yunwei Han
    Discover Oncology.2025;[Epub]     CrossRef
  • Sorafenib with or without co-interventions for hepatocellular carcinoma
    Shanshan Chen, Jian Ping Liu, Xinyu Li, Shoutao Dang, Wei Li
    Cochrane Database of Systematic Reviews.2025;[Epub]     CrossRef
  • Recent Advances in Combination Therapy of YAP Inhibitors with Physical Anti-Cancer Strategies
    Junchi Zhou, Changyan Yu, Wanhong Yang, Nian Jiang, Sanhua Li, Yun Liu, Xinting Zhu
    Biomolecules.2025; 15(7): 945.     CrossRef
  • Role of immune checkpoint inhibitor combinations in resectable and unresectable, embolization-eligible hepatocellular carcinoma
    Brandon M. Meyers, Howard J. Lim, Mayur Brahmania, Dave M. Liu, Vincent C. Tam, Deanna McLeod, Ravi Ramjeesingh, Jennifer J. Knox, Arndt Vogel
    Therapeutic Advances in Medical Oncology.2025;[Epub]     CrossRef
  • Synergies between radiotherapy and immunotherapy: a systematic review from mechanism to clinical application
    JingLong Jiang, HouZe Li, QingCui Ma, Jing Liu, Fu Ren, YingQiu Song, TianLu Wang, KeYan Li, Ning Li
    Frontiers in Immunology.2025;[Epub]     CrossRef
  • Local therapy overcomes primary resistance to target-immunotherapy combination in unresectable hepatocellular carcinoma
    Xiangqi Chen, Mingjian Piao, Zixiang Zhou, Shanshan Wang, Shuofeng Li, Nan Zhang, Boyu Sun, Kai Liu, Xu Yang, Xiaobo Yang, Xiaohua Shi, Chengpei Zhu, Haitao Zhao
    Cancer Immunology, Immunotherapy.2025;[Epub]     CrossRef
  • Immunotherapy change overcomes acquired resistance after chemo-immunotherapy in unresectable biliary tract cancer
    Xiangqi Chen, Zixiang Zhou, Shuofeng Li, Guanhua Yu, Shi Feng, Ze Zhou, Boyu Sun, Shanshan Wang, Kai Liu, Chengjie Li, Mingjian Piao, Mingming Wang, Yihong Zhang, Hu Li, Chengpei Zhu, Zhenyu Zhu, Haitao Zhao
    Cancer Immunology, Immunotherapy.2025;[Epub]     CrossRef
  • Molecular mechanisms underlying the abscopal effect induced by radiotherapy and its synergistic translational potential with immunotherapy
    Xinyi Chen, Mu Yang, Yongbiao Huang, Jingyao Tu, Yuwen Cai, Xianglin Yuan
    Therapeutic Advances in Medical Oncology.2025;[Epub]     CrossRef
  • Hepatocellular Carcinoma Showing Tumor Shrinkage Due to an Abscopal Effect
    Ryo Yano, Masashi Hirooka, Makoto Morita, Yuki Okazaki, Yoshiko Nakamura, Yusuke Imai, Takao Watanabe, Yohei Koizumi, Osamu Yoshida, Yoshio Tokumoto, Masanori Abe, Yoichi Hiasa
    Internal Medicine.2024; 63(2): 241.     CrossRef
  • Multidisciplinary treatment for patients with advanced hepatocellular carcinoma complicated by Vp4 portal vein tumor thrombosis: Combination of atezolizumab and bevacizumab after hepatic arterial infusion chemotherapy and radiotherapy: A case series
    Kenji Yamaoka, Tomokazu Kawaoka, Yasutoshi Fujii, Shinsuke Uchikawa, Hatsue Fujino, Takashi Nakahara, Atsushi Ohno, Eisuke Murakami, Daiki Miki, Masataka Tsuge, Keigo Chosa, Kazuo Awai, Junichi Hirokawa, Yasushi Nagata, Shiro Oka
    Medicine: Case Reports and Study Protocols.2024; 5(6): e00325.     CrossRef
  • Enhancing Magnetic Hyperthermia Efficacy through Targeted Heat Shock Protein 90 Inhibition: Unveiling Immune-Mediated Therapeutic Synergy in Glioma Treatment
    Ruby Gupta, Anjali Chauhan, Tashmeen Kaur, Bijoy Kumar Kuanr, Deepika Sharma
    ACS Nano.2024; 18(26): 17145.     CrossRef
  • Lymphatic system regulation of anti-cancer immunity and metastasis
    Pin-Ji Lei, Cameron Fraser, Dennis Jones, Jessalyn M. Ubellacker, Timothy P. Padera
    Frontiers in Immunology.2024;[Epub]     CrossRef
  • Research Progress on Dendritic Cells in Hepatocellular Carcinoma Immune Microenvironments
    Wenya Li, Guojie Chen, Hailin Peng, Qingfang Zhang, Dengyun Nie, Ting Guo, Yinxing Zhu, Yuhan Zhang, Mei Lin
    Biomolecules.2024; 14(9): 1161.     CrossRef
  • Evaluation of Treatments with Radiotherapy Alone and Radiotherapy Plus Chemo-immunotherapy in Patients with Primary Liver Cancer based on Blood Biomarkers
    Shigao Huang, Yutian Yin, Jianping Li, Mei Shi, Huijie Bian, Lina Zhao
    Current Medicinal Chemistry.2024; 31(40): 6586.     CrossRef
  • Novel VEGFR2 inhibitors with thiazoloquinoxaline scaffold targeting hepatocellular carcinoma with lower cardiotoxic impact
    Reham M. M. El-Hazek, Nashwa H. Zaher, Mostafa G. M. El-Gazzar, Noha A. Fadel, Walaa A. El-Sabbagh
    Scientific Reports.2023;[Epub]     CrossRef
  • The paradoxical role of radiation‐induced cGAS–STING signalling network in tumour immunity
    Xiaoyi Zhang, Han Zhang, Jiajia Zhang, Mengdie Yang, Mengqin Zhu, Yuzhen Yin, Xin Fan, Fei Yu
    Immunology.2023; 168(3): 375.     CrossRef
  • Comparison of stereotactic body radiotherapy with and without lenvatinib for advanced hepatocellular carcinoma: a propensity score analysis
    Quan Wang, Xiaoquan Ji, Jing Sun, Wengang Li, Xuezhang Duan, Aimin Zhang
    Journal of Cancer Research and Clinical Oncology.2023; 149(10): 7441.     CrossRef
  • Hepatocellular carcinoma (HCC) immunotherapy by anti-PD-1 monoclonal antibodies: A rapidly evolving strategy
    Marzieh Nikoo, Zahraa F. Hassan, Mahsa Mardasi, Elmira Rostamnezhad, Fatemeh Roozbahani, Sahel Rahimi, Javad Mohammadi
    Pathology - Research and Practice.2023; 247: 154473.     CrossRef
  • Combined radiotherapy and immune checkpoint inhibition for the treatment of advanced hepatocellular carcinoma
    Alexander H. Shannon, Ashish Manne, Dayssy A. Diaz Pardo, Timothy M. Pawlik
    Frontiers in Oncology.2023;[Epub]     CrossRef
  • Radiation and Immune Checkpoint Inhibitors: Combination Therapy for Treatment of Hepatocellular Carcinoma
    Perla Chami, Youssef Diab, Danny N. Khalil, Hassan Azhari, William R. Jarnagin, Ghassan K. Abou-Alfa, James J. Harding, Joseph Hajj, Jennifer Ma, Maria El Homsi, Marsha Reyngold, Christopher Crane, Carla Hajj
    International Journal of Molecular Sciences.2023; 24(23): 16773.     CrossRef
  • Inducing the Abscopal Effect in Liver Cancer Treatment: The Impact of Microwave Ablation Power Levels and PD-1 Antibody Therapy
    Changli Liao, Guiyuan Zhang, Ruotong Huang, Linyuan Zeng, Bin Chen, Haitao Dai, Keyu Tang, Run Lin, Yonghui Huang
    Pharmaceuticals.2023; 16(12): 1672.     CrossRef
  • Prognostic significance of albumin–bilirubin score in patients with unresectable hepatocellular carcinoma undergoing combined immunotherapy and radiotherapy
    Dezuo Dong, Xianggao Zhu, Hongzhi Wang, Lijuan Li, Meng Wan, Shuai Li, Yangzi Zhang, Jianhao Geng, Yongheng Li, Weihu Wang
    Journal of Medical Imaging and Radiation Oncology.2022; 66(5): 662.     CrossRef
  • Neoadjuvant Approaches in Hepatocellular Carcinoma: There's No Time Like the Present
    Joseph W. Franses, Andrew X. Zhu
    Clinical Cancer Research.2022; 28(13): 2738.     CrossRef
  • Crosstalk between tumor-associated macrophages and neighboring cells in hepatocellular carcinoma
    Pil Soo Sung
    Clinical and Molecular Hepatology.2022; 28(3): 333.     CrossRef
  • Combining stereotactic body radiotherapy with camrelizumab for unresectable hepatocellular carcinoma: a single-arm trial
    Jian-Xu Li, Ting-Shi Su, Wen-Feng Gong, Jian-Hong Zhong, Liu-Ying Yan, Jie Zhang, Li-Qing Li, Mei-Ling He, Rui-Jun Zhang, You-Qin Du, Xiao-Ting Wang, Shi-Xiong Liang, Bang-De Xiang
    Hepatology International.2022; 16(5): 1179.     CrossRef
  • PD-1/PD-L1 checkpoint inhibitors in advanced hepatocellular carcinoma immunotherapy
    Qian Li, Jingjing Han, Yonglin Yang, Yu Chen
    Frontiers in Immunology.2022;[Epub]     CrossRef
  • An Abscopal Effect in a Gastric Cancer Patient Treated with Combined Chemoimmunotherapy and Palliative Radiotherapy
    Zengtao Bao, Qiang Tang, Huiyu Chen, Baoming Zhang, Wenchao Shi, Dezhi Gu
    Immunotherapy.2022; 14(18): 1429.     CrossRef
  • Exploring the mythical abscopal effect: Radiation and programmed cell death protein 1 (PD-1) blockade for hepatocellular carcinoma
    Jun Won Kim, Ik Jae Lee
    Clinical and Molecular Hepatology.2021; 27(1): 103.     CrossRef
  • Manganese Ferrite Nanoparticles Enhance the Sensitivity of Hepa1-6 Hepatocellular Carcinoma to Radiation by Remodeling Tumor Microenvironments
    Sung-Won Shin, Kyungmi Yang, Miso Lee, Jiyoung Moon, Arang Son, Yeeun Kim, Suha Choi, Do-hyung Kim, Changhoon Choi, Nohyun Lee, Hee Chul Park
    International Journal of Molecular Sciences.2021; 22(5): 2637.     CrossRef
  • Immunogenic Cell Death Induction by Ionizing Radiation
    Mengqin Zhu, Mengdie Yang, Jiajia Zhang, Yuzhen Yin, Xin Fan, Yu Zhang, Shanshan Qin, Han Zhang, Fei Yu
    Frontiers in Immunology.2021;[Epub]     CrossRef
  • Current role of proton beam therapy in patients with hepatocellular carcinoma
    Gyu Sang Yoo, Jeong Il Yu, Hee Chul Park
    International Journal of Gastrointestinal Intervention.2021; 10(4): 175.     CrossRef
  • Antigen-Capturing Mesoporous Silica Nanoparticles Enhance the Radiation-Induced Abscopal Effect in Murine Hepatocellular Carcinoma Hepa1-6 Models
    Kyungmi Yang, Changhoon Choi, Hayeong Cho, Won-Gyun Ahn, Shin-Yeong Kim, Sung-Won Shin, Yeeun Kim, Taekyu Jang, Nohyun Lee, Hee Chul Park
    Pharmaceutics.2021; 13(11): 1811.     CrossRef
  • 13,503 View
  • 354 Download
  • 38 Web of Science
  • Crossref
Analysis of prognostic factors and 5-year survival rate in patients with hepatocellular carcinoma: a single-center experience
Sang Seok Lee, Hyun Sung Shin, Hyung Joon Kim, Su Jin Lee, Hyun Suk Lee, Kyung Hee Hyun, Yong Hyun Kim, Byoung Woon Kwon, Jin Hyung Han, Hoon Choi, Bae Hwan Kim, Joon Hyuk Lee, Ha Yan Kang, Hyun Deok Shin, Il Han Song
Korean J Hepatol 2012;18(1):48-55.
Published online March 22, 2012
DOI: https://doi.org/10.3350/kjhep.2012.18.1.48
Background/Aims

Hepatocellular carcinoma (HCC), which is the third most common cancer in Korea, has a very poor prognosis. However, only a few studies have performed a comprehensive survival-related analysis in all patients who were consecutively diagnosed and treated over a given period of time. The aim of this study was to determine the 5-year survival rate and its prognostic factors among HCC patients.

Methods

In total, 257 patients who were consecutively diagnosed with HCC between January 2000 and December 2003 were followed until death or until December 2008. We analyzed their survival outcomes according to their clinical characteristics, tumor staging, and treatment modalities, and determined the independent prognostic factors affecting survival.

Results

The patients were aged 59±10 years (mean±SD). During the follow-up period, 223 patients (86.8%) died and the overall median survival was 10.8 months; the 1-, 3-, and 5-year survival rates were 44.4%, 21.0%, and 12.1%, respectively. The outcomes in patients with tumor node metastasis (TNM) stage I or II and Child-Pugh class A or B were significantly better with surgical resection than with other treatment modalities (P<0.01). Patients who underwent supplementary transcatheter arterial chemoembolization as a second-line treatment after surgical resection had better outcomes than those who underwent surgical resection alone (P=0.02). Initial symptoms, Child-Pugh class, serum alpha-fetoprotein, tumor size, portal vein thrombosis, and TNM stage were found to be independent prognostic factors for survival among HCC patients.

Conclusions

This retrospective cohort study elucidated survival outcomes and prognostic factors affecting survival in HCC patients at a single center.

Citations

Citations to this article as recorded by  Crossref logo
  • Bioinformatics mining and clinical validation of CD274 as a prognostic indicator in hepatocellular carcinoma
    Hansen Shi, Peijun Zhang, Qiping Wei, Huixiang He, Haiqi Wu, Tianyin Xiao, Tiancai Liu, Tao Zeng
    BMC Cancer.2026;[Epub]     CrossRef
  • Deciphering the influence of AP1M2 in modulating hepatocellular carcinoma growth and Mobility through JNK/ErK signaling pathway control
    Huan Wang, Xin Xie, Minwei Du, Xintong Wang, Kunyuan Wang, Xingyuan Chen, Hui Yang
    Gene.2025; 933: 148955.     CrossRef
  • Risk Factor Analysis of Death in Patients With Hepatic Cellular Carcinoma After Radical Operation: A Consecutive Cohort of 433 Patients
    Zhengyang He, Wenfeng Lu, Dongze Qiu, Weimin She
    Health Science Reports.2025;[Epub]     CrossRef
  • Insulin-Like Growth Factor 1 Receptor Drives Hepatocellular Carcinoma Growth and Invasion by Activating Stat3-Midkine-Stat3 Loop
    Caiqun Bie, Yanfang Chen, Huijun Tang, Qing Li, Lu Zhong, Xiaojuan Peng, Ying Shi, Junqin Lin, Junlong Lai, Shenglan Wu, Shaohui Tang
    Digestive Diseases and Sciences.2022; 67(2): 569.     CrossRef
  • Hepatocellular Carcinoma (HCC) in North-Western India: A Retrospective Study Focusing on Epidemiology, Risk Factors, and Survival
    Sweta Soni, Puneet Pareek, Satya narayan, Amrita Rakesh, Abhilasha Abhilasha
    Journal of Gastrointestinal Cancer.2022; 53(4): 921.     CrossRef
  • Zingerone suppresses proliferation, invasion, and migration of hepatocellular carcinoma cells by the inhibition of MTDH-mediated PI3K/Akt pathway
    Jian Fang, Huifen Zhu, Pengcheng Xu, Renya Jiang
    Journal of Receptors and Signal Transduction.2022; 42(4): 409.     CrossRef
  • Comprehensive Analysis of Prognostic Value and Immune Infiltration of the NT5DC Family in Hepatocellular Carcinoma
    Rongqi Li, Rongqiang Liu, Shiyang Zheng, Wenbin Liu, Hui Li, Dewei Li, Alessandro Granito
    Journal of Oncology.2022; 2022: 1.     CrossRef
  • Integrated Analysis Revealing the Senescence-Mediated Immune Heterogeneity of HCC and Construction of a Prognostic Model Based on Senescence-Related Non-Coding RNA Network
    Yanan Jiang, Kunpeng Luo, Jincheng Xu, Xiuyun Shen, Yang Gao, Wenqi Fu, Xuesong Zhang, Hongguang Wang, Bing Liu
    Frontiers in Oncology.2022;[Epub]     CrossRef
  • Cross-Linked Multimeric Pro-Peptides of Type III Collagen (PC3X) in Hepatocellular Carcinoma – A Biomarker That Provides Additional Prognostic Value in AFP Positive Patients


    Christina Jensen, Signe Holm Nielsen, Mohammed Eslam, Federica Genovese, Mette Juul Nielsen, Roslyn Vongsuvanh, Raj Uchila, David van der Poorten, Jacob George, Morten Asser Karsdal, Diana Julie Leeming, Nicholas Willumsen
    Journal of Hepatocellular Carcinoma.2020; Volume 7: 301.     CrossRef
  • Clinical characteristics and prognosis of 2887 patients with hepatocellular carcinoma
    Chun-yan Wang, Shengmian Li
    Medicine.2019; 98(4): e14070.     CrossRef
  • Analyses of a Panel of Transcripts Identified From a Small Sample Size and Construction of RNA Networks in Hepatocellular Carcinoma
    Zhiyong Sheng, Xiaolin Wang, Geliang Xu, Ge Shan, Liang Chen
    Frontiers in Genetics.2019;[Epub]     CrossRef
  • Validation of modified albumin-bilirubin-TNM score as a prognostic model to evaluate patients with hepatocellular carcinoma
    Omar Elshaarawy, Alzhraa Alkhatib, Mostafa Elhelbawy, Asmaa Gomaa, Naglaa Allam, Ayman Alsebaey, Eman Rewisha, Imam Waked
    World Journal of Hepatology.2019; 11(6): 542.     CrossRef
  • A new prognostic score can predict survival after hepatocellular carcinoma treatment in a cohort of 1302 Egyptian hepatocellular carcinoma patients
    Ashraf O. Abdelaziz, Hend I. Shousha, Ahmed H. Abdelmaksoud, Yasmin Saad, Tamer M. Elbaz, Zeinab A. Soliman, Ayman Salah, Rania Lithy, Mona Ahmed, Mohamed M. Nabil
    European Journal of Gastroenterology & Hepatology.2018; 30(5): 514.     CrossRef
  • The SMYD3 VNTR 3/3 polymorphism confers an increased risk and poor prognosis of hepatocellular carcinoma in a Chinese population
    Rui-Dong Li, Yan-Hua Tang, Hui-Li Wang, Dong Yang, Li-Jun Sun, Wei Li
    Pathology - Research and Practice.2018; 214(5): 625.     CrossRef
  • Somatostatin receptors in resected hepatocellular carcinoma: status and correlation with markers of poor prognosis
    Marie Lequoy, Christèle Desbois‐Mouthon, Dominique Wendum, Vandana Gupta, Jean‐Luc Blachon, Olivier Scatton, Sylvie Dumont, Mireille Bonnemaire, Fabien Schmidlin, Olivier Rosmorduc, Laetitia Fartoux
    Histopathology.2017; 70(3): 492.     CrossRef
  • Fibro markers for prediction of hepatocellular carcinoma in Egyptian patients with chronic liver disease
    Lamiaa Mobarak, Dalia Omran, Mohammed M. Nabeel, Zeinab Zakaria
    Journal of Medical Virology.2017; 89(6): 1062.     CrossRef
  • Prognostic Value of FDG Uptake of Portal Vein Tumor Thrombosis in Patients With Locally Advanced Hepatocellular Carcinoma
    Jeong Won Lee, Sang Hyun Hwang, Do Young Kim, Kwang-Hyub Han, Mijin Yun
    Clinical Nuclear Medicine.2017; 42(1): e35.     CrossRef
  • Anti-GPC3-CAR T Cells Suppress the Growth of Tumor Cells in Patient-Derived Xenografts of Hepatocellular Carcinoma
    Zhiwu Jiang, Xiaofeng Jiang, Suimin Chen, Yunxin Lai, Xinru Wei, Baiheng Li, Simiao Lin, Suna Wang, Qiting Wu, Qiubin Liang, Qifa Liu, Muyun Peng, Fenglei Yu, Jianyu Weng, Xin Du, Duanqing Pei, Pentao Liu, Yao Yao, Ping Xue, Peng Li
    Frontiers in Immunology.2017;[Epub]     CrossRef
  • Secreted phosphoprotein 24 kD (Spp24) inhibits growth of hepatocellular carcinoma in vivo
    Lifeng Lao, Jia Shen, Haijun Tian, Guibin Zhong, Samuel S. Murray, Jeffrey C. Wang
    Environmental Toxicology and Pharmacology.2017; 51: 51.     CrossRef
  • XRCC1 and XPD polymorphisms and their relation to the clinical course in hepatocarcinoma patients
    Qinghai Guan, Zhiqiang Chen, Qiangpu Chen, Xuting Zhi
    Oncology Letters.2017; 14(3): 2783.     CrossRef
  • Clinical effects of miR-101 on prognosis of hepatocellular carcinoma and carcinogenic mechanism of anti-miR-101
    Xuecheng Lv, Jinghua Li, Bingnan Yang
    Oncology Reports.2016; 36(4): 2184.     CrossRef
  • Importance of SALL4 in the development and prognosis of hepatocellular carcinoma
    Fei Yin, Xin Han, Shu-Kun Yao, Xiao-Ling Wang, Hui-Chai Yang
    World Journal of Gastroenterology.2016; 22(9): 2837.     CrossRef
  • Multipotent mesenchymal stromal cells: A promising strategy to manage alcoholic liver disease
    Fernando Ezquer
    World Journal of Gastroenterology.2016; 22(1): 24.     CrossRef
  • Mitochondrial DNA Copy Number in Egyptian Patients with Hepatitis C Virus-Related Hepatocellular Carcinoma
    Doaa I. Hashad, Amany S. Elyamany, Perihan E. Salem
    Genetic Testing and Molecular Biomarkers.2015; 19(11): 604.     CrossRef
  • Comparison of Transarterial Chemoembolization and Hepatic Resection for Large Solitary Hepatocellular Carcinoma: A Propensity Score Analysis
    Yun Bin Lee, Dong Hyeon Lee, Yuri Cho, Su Jong Yu, Jeong-Hoon Lee, Jung-Hwan Yoon, Hyo-Suk Lee, Hyo-Cheol Kim, Nam-Joon Yi, Kwang-Woong Lee, Kyung-Suk Suh, Jin Wook Chung, Yoon Jun Kim
    Journal of Vascular and Interventional Radiology.2015; 26(5): 651.     CrossRef
  • Vascular invasion in hepatitis B virus-related hepatocellular carcinoma with underlying cirrhosis: possible associations with ascites and hepatitis B viral factors?
    Chuan Chen, Dong-Ping Chen, Yan-Yan Gu, Liang-Hao Hu, Dan Wang, Jin-Huan Lin, Zhao-Shen Li, Jing Xu, Ge Wang
    Tumor Biology.2015; 36(8): 6255.     CrossRef
  • Prognostic Significance of Preoperative Serum Alpha-fetoprotein in Hepatocellular Carcinoma and Correlation with Clinicopathological Factors: a Single-center Experience from China
    Song-Lin An, Ting Xiao, Li-Ming Wang, Wei-Qi Rong, Fan Wu, Li Feng, Fa-Qiang Liu, Fei Tian, Jian-Xiong Wu
    Asian Pacific Journal of Cancer Prevention.2015; 16(10): 4421.     CrossRef
  • High circulating microRNA-122 expression is a poor prognostic marker in patients with hepatitis B virus-related hepatocellular carcinoma who undergo radiofrequency ablation
    Hyo Jung Cho, Jai Keun Kim, Ji Sun Nam, Hee Jung Wang, Jei Hee Lee, Bong Wan Kim, Soon Sun Kim, Choong Kyun Noh, Sung Jae Shin, Kee Myung Lee, Sung Won Cho, Jae Youn Cheong
    Clinical Biochemistry.2015; 48(16-17): 1073.     CrossRef
  • Impact of postoperative hepatitis B virus reactivation in hepatocellular carcinoma patients who formerly had naturally suppressed virus
    Jung Il Lee, Ja Kyung Kim, Hye Young Chang, Jin‐Woo Lee, Joon Mee Kim, Hyun Jung Chung, Young Soo Kim, Kwan Sik Lee
    Journal of Gastroenterology and Hepatology.2014; 29(5): 1019.     CrossRef
  • Assessing Prognostic Significance of Preoperative Alpha-Fetoprotein in Hepatitis B-Associated Hepatocellular Carcinoma: Normal is not the New Normal
    Sima Blank, Qin Wang, M. Isabel Fiel, Wei Luan, Ki Won Kim, Hena Kadri, John Mandeli, Spiros P. Hiotis
    Annals of Surgical Oncology.2014; 21(3): 986.     CrossRef
  • Histological improvement following administration of autologous bone marrow‐derived mesenchymal stem cells for alcoholic cirrhosis: a pilot study
    Yoon Ok Jang, Young Ju Kim, Soon Koo Baik, Moon Young Kim, Young Woo Eom, Mee Yon Cho, Hong Jun Park, So Yeon Park, Bo Ra Kim, Jae Woo Kim, Hyun Soo Kim, Sang Ok Kwon, Eun Hee Choi, Yong Man Kim
    Liver International.2014; 34(1): 33.     CrossRef
  • Effect of bone marrow-derived mesenchymal stem cells on hepatic fibrosis in a thioacetamide-induced cirrhotic rat model
    Yoon Ok Jang, Moon Young Kim, Mee Yon Cho, Soon Koo Baik, Youn Zoo Cho, Sang Ok Kwon
    BMC Gastroenterology.2014;[Epub]     CrossRef
  • Survival and Prognostic Factors for Hepatocellular Carcinoma: an Egyptian Multidisciplinary Clinic Experience
    Ashraf Omar Abdelaziz, Tamer Mahmoud Elbaz, Hend Ibrahim Shousha, Mostafa Mohamed Ibrahim, Mostafa Abdel Rahman El-Shazli, Ahmed Hosni Abdelmaksoud, Omar Abdel Aziz, Hisham Atef Zaki, Inas Anwar Elattar, Mohamed Mahmoud Nabeel
    Asian Pacific Journal of Cancer Prevention.2014; 15(9): 3915.     CrossRef
  • Lesson from 610 liver resections of hepatocellular carcinoma in a single center over 10 years
    Dai Hoon Han, Gi Hong Choi, Jun Yong Park, Sang Hoon Ahn, Kyung Sik Kim, Jin Sub Choi, Kwang-Hyub Han
    World Journal of Surgical Oncology.2014;[Epub]     CrossRef
  • Management of Hepatocellular Carcinoma: Updated Review
    Tamer Elbaz, Mohamed El Kassas, Gamal Esmat
    Journal of Cancer Therapy.2013; 04(02): 536.     CrossRef
  • 12,561 View
  • 56 Download
  • Crossref
Effects of the knockdown of hypoxia inducible factor-1α expression by adenovirus-mediated shRNA on angiogenesis and tumor growth in hepatocellular carcinoma cell lines
Sung Hoon Choi, Hye Won Shin, Jun Yong Park, Ji Young Yoo, Do Young Kim, Weon Sang Ro, Chae-Ok Yun, Kwang-Hyub Han
Korean J Hepatol 2010;16(3):280-287.
Published online September 30, 2010
DOI: https://doi.org/10.3350/kjhep.2010.16.3.280
Background/Aims

Hypoxia-inducible factor-1α (HIF-1α) is a central transcriptional factor involved in the cellular responses related to various aspects of cancer biology, including proliferation, survival, and angiogenesis, and the metabolism of the extracellular matrix in hypoxia. This study evaluated whether adenovirus-mediated small hairpin RNA (shRNA) against HIF-1α (shHIF-1α) inhibits cell proliferation and angiogenesis in hepatocellular carcinoma (HCC) cell lines.

Methods

Knockdown of HIF-1α expression was constructed by adenovirus-mediated RNA interference tools, and HCC cell lines infected with shHIF-1α coding virus were cultured under a hypoxia condition (1% O2) for 24 hours. Following infection, the expression levels of HIF-1α, angiogenesis factors, and matrix metalloproteinase (MMP) were examined using Western blotting. Cell proliferation and angiogenesis were measured by a cell proliferation assay (MTT assay) and an angiogenesis-related assay (invasion and tube-formation assay), respectively.

Results

Adenovirus mediated inhibition of HIF-1α induced suppression of tumor growth in HCC cell lines. It also down-regulated the expression of angiogenesis factor and MMP proteins. Angiogenesis as well as mobility of vascular cells to tumor was suppressed by adenovirus-mediated shHIF-1α-infected groups in human umbilical vein endothelial cells (HUVECs).

Conclusions

These data suggest that adenovirus-mediated inhibition of HIF-1α inhibits the invasion, tube formation, and cell growth in HUVECs and HCC cells.

Citations

Citations to this article as recorded by  Crossref logo
  • Therapeutic Synergy of Silibinin‐Loaded Nanogel and Low‐Dose Gamma Radiation in Hepatocellular Carcinoma: Emphasis on EMT, Angiogenesis, and Immune Response
    Zakaria Mohamed Alghzzawy, Mohammed Hussein Awwad, Tarek Khaled Elmaghraby, Sanaa Abd El‐Hamid Hagag, Azza Elsayed Kayed, Doaa Sabry Ibrahim
    Advanced Therapeutics.2025;[Epub]     CrossRef
  • RSK2-Mediated ELK3 Activation Enhances Cell Transformation and Breast Cancer Cell Growth by Regulation of c-fos Promoter Activity
    Sun-Mi Yoo, Cheol-Jung Lee, Hyun-Jung An, Joo Young Lee, Hye Suk Lee, Han Chang Kang, Sung-Jun Cho, Seung-Min Kim, Juhee Park, Dae Joon Kim, Yong-Yeon Cho
    International Journal of Molecular Sciences.2019; 20(8): 1994.     CrossRef
  • Stable knockdown of CREB, HIF-1 and HIF-2 by replication-competent retroviruses abrogates the responses to hypoxia in hepatocellular carcinoma
    D Shneor, R Folberg, J Pe'er, A Honigman, S Frenkel
    Cancer Gene Therapy.2017; 24(2): 64.     CrossRef
  • Tumor angiogenesis and vascular normalization: alternative therapeutic targets
    Claire Viallard, Bruno Larrivée
    Angiogenesis.2017; 20(4): 409.     CrossRef
  • ELK3 promotes the migration and invasion of liver cancer stem cells by targeting HIF-1α
    Joon Ho Lee, Wonhee Hur, Sung Woo Hong, Jung-Hee Kim, Sung Min Kim, Eun Byul Lee, Seung Kew Yoon
    Oncology Reports.2017; 37(2): 813.     CrossRef
  • RNAi Knockdown of Hypoxia-Inducible Factor-1α Decreased the Proliferation, Migration, and Invasion of Hypoxic Hepatocellular Carcinoma Cells
    ChengShi Chen, Rong Liu, JianHua Wang, ZhiPing Yan, Sheng Qian, Wei Zhang
    Cell Biochemistry and Biophysics.2015; 71(3): 1677.     CrossRef
  • Inhibition of tumour angiogenesis and growth by small hairpin HIF‐1α and IL‐8 in hepatocellular carcinoma
    Sung Hoon Choi, Oh‐Joon Kwon, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Seung Up Kim, Simon Weonsang Ro, Kyung Sik Kim, Jeon Han Park, Seungtaek Kim, Chae‐Ok Yun, Kwang‐Hyub Han
    Liver International.2014; 34(4): 632.     CrossRef
  • The Role of Hypoxia Inducible Factor-1 in Hepatocellular Carcinoma
    Dongjun Luo, Zhongxia Wang, Junyi Wu, Chunping Jiang, Junhua Wu
    BioMed Research International.2014; 2014: 1.     CrossRef
  • Expression and significance of MMP2 and HIF-1α in hepatocellular carcinoma
    BIN WANG, YOU-MING DING, PING FAN, BING WANG, JUN-HUI XU, WEI-XING WANG
    Oncology Letters.2014; 8(2): 539.     CrossRef
  • Signaling pathways bridging microbial-triggered inflammation and cancer
    Maulilio John Kipanyula, Paul Faustin Seke Etet, Lorella Vecchio, Mohammed Farahna, Elias Nchiwan Nukenine, Armel Hervé Nwabo Kamdje
    Cellular Signalling.2013; 25(2): 403.     CrossRef
  • The role of Aurora A in hypoxia-inducible factor 1α-promoting malignant phenotypes of hepatocelluar carcinoma
    Shi-Yun Cui, Jia-Yuan Huang, Yi-Tian Chen, Hai-Zhu Song, Gui-Chun Huang, Wei De, Rui Wang, Long-Bang Chen
    Cell Cycle.2013; 12(17): 2849.     CrossRef
  • Hypoxia-inducible factor 1, hepatocellular carcinoma and angiogenesis
    Jin-Wook Kim
    The Korean Journal of Hepatology.2010; 16(3): 278.     CrossRef
  • 12,472 View
  • 68 Download
  • Crossref